{"id":9875,"date":"2016-09-05T08:10:51","date_gmt":"2016-09-05T08:10:51","guid":{"rendered":"http:\/\/revoscience.com\/en\/?p=9875"},"modified":"2016-09-05T08:10:51","modified_gmt":"2016-09-05T08:10:51","slug":"amgen-posts-phase-3-data-for-bone-drug-blockbuster","status":"publish","type":"post","link":"https:\/\/www.revoscience.com\/en\/amgen-posts-phase-3-data-for-bone-drug-blockbuster\/","title":{"rendered":"Amgen Posts Phase 3 Data for Bone Drug Blockbuster"},"content":{"rendered":"<div class=\"panel-pane pane-entity-field pane-node-field-body-paragraphs\">\n<div class=\"pane-content\">\n<div class=\"paragraphs-items paragraphs-items-field-body-paragraphs paragraphs-items-field-body-paragraphs-full paragraphs-items-full\">\n<div class=\"field field-name-field-body-paragraphs field-type-paragraphs field-label-hidden\">\n<div class=\"field-items\">\n<div class=\"field-item odd\">\n<div class=\"entity entity-paragraphs-item paragraphs-item-embedded-text\" style=\"font-weight: normal;\">\n<div class=\"content\">\n<div class=\"field field-name-field-embedded-text field-type-text-long field-label-hidden\">\n<div class=\"field-items\">\n<div class=\"field-item even\">\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\"><a href=\"http:\/\/revoscience.com\/en\/wp-content\/uploads\/2016\/09\/ddd1609_bones_Amgen-1.jpg\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-9877\" src=\"http:\/\/revoscience.com\/en\/wp-content\/uploads\/2016\/09\/ddd1609_bones_Amgen-1.jpg\" alt=\"ddd1609_bones_Amgen (1)\" width=\"800\" height=\"534\" title=\"\" srcset=\"https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/09\/ddd1609_bones_Amgen-1.jpg 800w, https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/09\/ddd1609_bones_Amgen-1-300x200.jpg 300w\" sizes=\"auto, (max-width: 800px) 100vw, 800px\" \/><\/a>Amgen\u2019s Prolia could soon gain another indication.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">The company published promising Phase 3 results from a study evaluating the safety and efficacy of Prolia for patients diagnosed with glucocorticoid-induced osteoporosis. It was compared with risedronate, which is another drug that targets osteoporosis.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">A total of 795 patients enrolled in this 24-month-long study. Investigators administered 60 milligrams subcutaneously of Prolia to participants while two other patient subpopulations took daily 5 milligrams of oral risedronate,\u00a0<a style=\"color: inherit;\" href=\"http:\/\/www.prnewswire.com\/news-releases\/amgen-announces-positive-top-line-results-from-phase-3-study-of-prolia-denosumab-in-patients-receiving-glucocorticoid-therapy-300319150.html\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #000000;\">according to Amgen\u2019s announcement.<\/span><\/a><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">Prolia achieved both primary and secondary endpoints at 12 months. It had a stronger showing when it came to restoring bone mineral density at the lumbar spine and total hip regions with reported cases of adverse events and serious adverse events being consistent with Prolia\u2019s current safety profile.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">&#8220;The impact of glucocorticoid therapy on bone strength is frequently underestimated, and often leads to increased bone loss and ultimately, a fracture,&#8221; said Dr. Sean E. Harper, Amgen\u2019s executive vice president of Research and Development in a statement.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">&#8220;We are excited that these data support the potential for Prolia use in patients with glucocorticoid-induced osteoporosis, the most common drug-induced form of the disease,\u201d added Harper.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">This study is still ongoing, but it bodes well for Amgen,\u00a0<a style=\"color: inherit;\" href=\"http:\/\/www.fiercepharma.com\/marketing\/amgen-s-bone-drug-prolia-nabs-data-for-new-use-its-way-to-blockbuster-sales\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #000000;\">wrote\u00a0<em>FiercePharma.<\/em><\/span><\/a>\u00a0Prolia is slated to break the $1 billion blockbuster sales mark this year as it brought $286 million in sales so far this year. The drug made $837 million in 2015 too.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prolia achieved both primary and secondary endpoints at 12 months. It had a stronger showing when it came to restoring bone mineral density at the lumbar spine and total hip regions with reported cases of adverse events and serious adverse events being consistent with Prolia\u2019s current safety profile.<\/p>\n<p>&#8220;The impact of glucocorticoid therapy on bone strength is frequently underestimated, and often leads to increased bone loss and ultimately, a fracture,&#8221; said Dr. Sean E. Harper, Amgen\u2019s executive vice president of Research and Development in a statement.<\/p>\n","protected":false},"author":6,"featured_media":9877,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26,17],"tags":[],"class_list":["post-9875","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicine","category-research"],"featured_image_urls":{"full":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/09\/ddd1609_bones_Amgen-1.jpg",800,534,false],"thumbnail":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/09\/ddd1609_bones_Amgen-1-150x150.jpg",150,150,true],"medium":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/09\/ddd1609_bones_Amgen-1-300x200.jpg",300,200,true],"medium_large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/09\/ddd1609_bones_Amgen-1.jpg",750,501,false],"large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/09\/ddd1609_bones_Amgen-1.jpg",750,501,false],"1536x1536":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/09\/ddd1609_bones_Amgen-1.jpg",800,534,false],"2048x2048":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/09\/ddd1609_bones_Amgen-1.jpg",800,534,false],"ultp_layout_landscape_large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/09\/ddd1609_bones_Amgen-1.jpg",800,534,false],"ultp_layout_landscape":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/09\/ddd1609_bones_Amgen-1.jpg",800,534,false],"ultp_layout_portrait":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/09\/ddd1609_bones_Amgen-1.jpg",600,401,false],"ultp_layout_square":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/09\/ddd1609_bones_Amgen-1.jpg",600,401,false],"newspaper-x-single-post":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/09\/ddd1609_bones_Amgen-1.jpg",734,490,false],"newspaper-x-recent-post-big":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/09\/ddd1609_bones_Amgen-1.jpg",539,360,false],"newspaper-x-recent-post-list-image":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/09\/ddd1609_bones_Amgen-1.jpg",95,63,false],"web-stories-poster-portrait":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/09\/ddd1609_bones_Amgen-1.jpg",640,427,false],"web-stories-publisher-logo":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/09\/ddd1609_bones_Amgen-1.jpg",96,64,false],"web-stories-thumbnail":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/09\/ddd1609_bones_Amgen-1.jpg",150,100,false]},"author_info":{"info":["Amrita Tuladhar"]},"category_info":"<a href=\"https:\/\/www.revoscience.com\/en\/category\/health\/medicine\/\" rel=\"category tag\">Medicine<\/a> <a href=\"https:\/\/www.revoscience.com\/en\/category\/news\/research\/\" rel=\"category tag\">Research<\/a>","tag_info":"Research","comment_count":"0","_links":{"self":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts\/9875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/comments?post=9875"}],"version-history":[{"count":0,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts\/9875\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/media\/9877"}],"wp:attachment":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/media?parent=9875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/categories?post=9875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/tags?post=9875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}